Triple
T23186577
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | George D. Yancopoulos |
E579607
|
entity |
| Predicate | notableWork |
P4
|
FINISHED |
| Object | Regeneron’s VelocImmune platform |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regeneron’s VelocImmune platform | Statement: [George D. Yancopoulos, notableWork, Regeneron’s VelocImmune platform]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Regeneron’s VelocImmune platform Context triple: [George D. Yancopoulos, notableWork, Regeneron’s VelocImmune platform]
-
A.
VelocImmune technology
chosen
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
HyperAcute cellular immunotherapy platform
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
C.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Transigen
Transigen is a secretive biotech corporation in the X-Men/Logan universe that conducts unethical genetic experiments to create and control mutant weapons.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
Created at: April 17, 2026, 4:05 p.m.